Alzamend Neuro Doses First Patient in Phase II Trial of AL001 for Neurological Disorders
Alzamend Neuro announces dosing of first patient in Phase II trial of AL001, a lithium-based therapeutic for Alzheimer’s, bipolar disorder, MDD, and PTSD. Learn more about this breakthrough treatment here.
This news is significant as AL001 offers a novel approach to treating neurological disorders by improving drug delivery and reducing side effects. If successful, this therapy could transform the treatment landscape for Alzheimer’s, bipolar disorder, major depressive disorder, and PTSD.